Mumbai, Mar 11 (UNI) AstraZeneca Pharma India Limited and Mankind Pharma entered into an agreement for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India.
“India is contributing 13 per cent to the global asthma burden and a disproportionate 43 per cent of the global asthma deaths and we want to improve access to medicines strategically in the country,” said Dr Sanjeev Panchal, Country president and managing director, AstraZeneca India.
“… we are excited to partner with AstraZeneca to make their innovative therapy flagship brand, Symbicort — a global standard in treating asthma,” said Atish Majumdar, Sales & Marketing senior president, Mankind Pharma Limited.
